Skip to main content


Our team works seamlessly with the Life Sciences and Healthcare Regulatory practice group to provide comprehensive policy solutions to a broad range of clients, including: hospital systems, medical professional associations, medical devices/pharmaceuticals/biologics/medical supply manufacturers, diagnostic testing companies and labs, nonprofit research institutions, and healthcare technology companies. Our team members served in senior positions in Congress, at HHS, and are recognized by The Hill as top lobbyists. We have substantial experience on industry issues like Medicare and Medicaid coverage and reimbursement, drug pricing, Affordable Care Act implementation, healthcare program integrity policy, public health, and COVID-19 relief efforts. We also have extensive experience with Congressional oversight and investigations, securing federal funding, and coalitions.

Experience Highlights

  • Secured Medicare coverage for a client’s breakthrough medical device through a coordinated congressional and agency effort.
  • Representing manufacturers of pharmaceuticals, biologics, and diagnostic tests on various COVID-19 related matters, including securing critical infrastructure designations, federal funding, supply chain and other matters.
  • Secured reauthorization of a Health Resources and Services Administration workforce program in the COVID-19 relief legislation.
  • Blocked a nearly 70 percent payment reduction for in-home EEG services through an integrated legislative and regulatory strategy, including direct advocacy and coalition building.
  • Represented pharmaceutical manufacturers through Congressional investigations and oversight hearings related to pricing, patents, and innovation in current and prior Congresses.
  • Worked with healthcare systems to secure enactment of legislative reforms that support coordination of care provided to medically complex children.
  • Coordinated with other stakeholders, secured passage of legislation permanently repealing the excise tax on medical device manufacturers and importers.
  • Secured language in the House FY 2020 MilCon-VA appropriations bill to support a $2 million pressure ulcer prevention pilot program that uses the client’s technology.
  • Reversed a proposed 85% cut in Medicare payment for a molecular diagnostic test used to avoid unnecessary chemotherapy after breast cancer, through a rapid-response Congressional, regulatory and coalition strategy that protected the emerging precision medicine market and ensured Medicare beneficiaries would continue to have access to vital diagnostic tests.
  • Prepared key portions of a Supreme Court amicus brief on behalf of a coalition of healthcare data organizations supporting expanded access to inform state-level cost containment and quality improvement efforts.